Kevin Joseph Fitzgerald, CSO & EVP, Head of Research at ALNYLAM PHARMACEUTICALS, INC. (ALNY), sold 1,291 shares at $319.03 ($418K) on 2026-03-04, disclosed to the SEC on 2026-03-06.
Open-market sale of $418k ALNY by CSO & EVP, Head of Research. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $319.03 | 29 | $9K | 2.2% |
| 2 | $320.01 | 28 | $9K | 2.1% |
| 3 | $320.81 | 59 | $19K | 4.5% |
| 4 | $321.82 | 79 | $25K | 6.1% |
| 5 | $323.01 | 96 | $31K | 7.4% |
| 6 | $323.84 | 210 |
| $68K |
| 16.3% |
| 7 | $324.88 | 75 | $24K | 5.8% |
| 8 | $325.67 | 57 | $19K | 4.4% |
| 9 | $321.81 | 124 | $40K | 9.6% |
| 10 | $323.25 | 233 | $75K | 18.0% |
| 11 | $324.60 | 148 | $48K | 11.5% |
| 12 | $326.24 | 153 | $50K | 12.0% |
| Total | $323.54 avg | 1,291 | $418K | 100% |
| Filing → |
| ALNY | SELL | 2026-01-14 | $1.4M | — | Filing → |
| ALNY | SELL | 2025-11-19 | $7.1M | — | Filing → |
| ALNY | SELL | 2025-10-03 | $2.1M | — | Filing → |